1257213-50-5

Basic information

• Product Name: BMS-986020
• Synonyms: BMS-986020
• CAS NO: 1257213-50-5
• Molecular Formula: C₂₉H₂₆N₂O₅
• Molecular Weight: 482.52714
• Mol File: 1257213-50-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 664.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.309±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly, Sonicated)
• PKA: 4.19±0.20(Predicted)
• CAS DataBase Reference: BMS-986020(CAS DataBase Reference)
• NIST Chemistry Reference: BMS-986020(1257213-50-5)
• EPA Substance Registry System: BMS-986020(1257213-50-5)

Safety Data

• Hazardous Substances Data: 1257213-50-5(Hazardous Substances Data)

Usage

Description

BMS 986020 is a potent G protein-coupled lysophosphatidic acid receptor 1 (LPA1) antagonist with an IC50 value less than 300 nM for human LPA1 expressing CHO cells. Formulations containing BMS 986020 are being investigated in clinical trials for efficacy in idiopathic pulmonary fibrosis.

Uses

BMS-?986020 is an LPA-1 antagonist which may be used in the inhibition and treatment of bleomycin-induced pulminary fibrosis.

Upstream product

• 1215205-50-7 ethyl 1-(4-bromophenyl)cyclopropane-1-carboxylate 
• 1159489-46-9 [4-(1'-carboxycyclopropyl)phenyl]boronic acid 
• 345965-52-8 1-(4-bromophenyl)cyclopropanecarboxylic acid 
• 1228690-37-6 (R)-1-phenylethyl (5-(4-bromophenyl)-3-methylisoxazol-4-yl)carbamate 
• 1257213-52-7 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylic acid ethyl ester 
• 1517-69-7 (R)-1-phenylethanol 
• 1380650-69-0 5-(4'-(1-(isopropoxycarbonyl)cyclopropyl)biphenyl-4-yl)-3-methylisoxazole-4-carboxylic acid 
• 1380650-65-6 1-(4'-acetylbiphenyl-4-yl)cyclopropanecarboxylic acid isopropyl ester 
• 1380650-64-5 1-(biphenyl-4-yl)cyclopropanecarboxylic acid isopropyl ester 
• 1257214-10-0 5-(4'-(1-(ethoxycarbonyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-3-methylisoxazole-4-carboxylic acid 
• 1380650-62-3 benzyl 5-(4'-(1-(ethoxycarbonyl)cyclopropyl)biphenyl-4-yl)-3-methylisoxazole-4-carboxylate 
• 1380650-61-2 ethyl 1-(4'-(2-(benzyloxycarbonyl)-3-(methylamino)but-2-enoyl)biphenyl-4-yl)cyclopropanecarboxylate 
• 1380650-58-7 4'-(1-(ethoxycarbonyl)cyclopropyl)biphenyl-4-carboxylic acid 
• 1380650-56-5 1-(4'-acetylbiphenyl-4-yl)cyclopropanecarboxylic acid ethyl ester 

Downstream Products

• 1257214-49-5 {5-[4'-(1-methanesulfonylaminocarbonyl-cyclopropyl)-biphenyl-4-yl]-3-methyl-isoxazol-4-yl}-carbamic acid (R)-1-phenyl-ethyl ester 
• 1380650-53-2 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid sodium salt 

Relevant articles and documents

Development of a Concise Multikilogram Synthesis of LPA-1 Antagonist BMS-986020 via a Tandem Borylation-Suzuki Procedure

The process development for the synthesis of BMS-986020 (1) via a palladium catalyzed tandem borylation/Suzuki reaction is described. Evaluation of conditions culminated in an efficient borylation procedure using tetrahydroxydiboron followed by a tandem Suzuki reaction employing the same commercially available palladium catalyst for both steps. This methodology addressed shortcomings of early synthetic routes and was ultimately used for the multikilogram scale synthesis of the active pharmaceutical ingredient 1. Further evaluation of the borylation reaction showed useful reactivity with a range of substituted aryl bromides and iodides as coupling partners. These findings represent a practical, efficient, mild, and scalable method for borylation.

POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF

Described herein is the LPA1 antagonist 1- {4'-[3-methyl-4-((R)- l-phenyl-ethoxycarbonylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing t